Dr. Joy Kong compares three GLP-1 drugs: semaglutide (Ozempic, Wegovy), tirzepatide, which hits two receptors and may have fewer side effects, and retatrutide, which targets three receptors for stronger results. She breaks down which might work best depending on your tolerance and goals.
What's all this fuss about GLP-1 agonists? So people are talking about GLP-1, 2, 3, but really what's relevant to you is what actually works. So what are these? We're talking about the most popular one is semaglutide that was made very famous by the Kardashians, that would include Ozempic or Wegovy. So those two has revolutionized the weight loss industry, and then it comes to the tirzepatide, which is dual-acting. So it acts on GLP-1 and GIP receptors. So this peptide will give you less side effects and can work very well. Sometimes people use it in conjunction with the semaglutide, and that can work quite well as well. But the more popular one now is called retatrudide, and that one was— there was a misnomer, people call it GLP-3. It's really because it's acting on 3 receptors. That's GLP-1, GIP, and glucagon, and that's supposed to have superior efficacy. So that has been all the rage these days. So which one would you pick?
